Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.US based Inhibitex has started patient dosing in a placebo-controlled, randomized Phase 2 trial to investigate INX-189.
Subscribe to our email newsletter
The trial aims to investigate the safety, tolerability and antiviral activity of INX-189 in conjunction with pegylated interferon and ribavirin in chronic HCV-infected genotype 2 and 3 treatment naive patients.
The trial is intended to assess three once-daily doses of INX-189 (25 mg, 50 mg and 100 mg) administered in combination with pegylated interferon and ribavirin for 12 weeks.